Business Description
EyePoint Inc
NAICS : 325412
SIC : 2834
ISIN : US30233G2093
Total Employee Number:
214Description
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 11 | |||||
Equity-to-Asset | 0.8 | |||||
Debt-to-Equity | 0.09 | |||||
Debt-to-EBITDA | -0.08 | |||||
Piotroski F-Score | 1/9 | |||||
Altman Z-Score | 4.09 | |||||
Beneish M-Score | 12.81 | |||||
WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -27.2 | |||||
3-Year EBITDA Growth Rate | -6.5 | |||||
3-Year EPS without NRI Growth Rate | -13.9 | |||||
3-Year FCF Growth Rate | -22.7 | |||||
3-Year Book Growth Rate | 9.3 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 22.39 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 42.45 | |||||
9-Day RSI | 48.86 | |||||
14-Day RSI | 51.03 | |||||
3-1 Month Momentum % | -17.43 | |||||
6-1 Month Momentum % | -23.74 | |||||
12-1 Month Momentum % | 22.76 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 6.66 | |||||
Quick Ratio | 6.63 | |||||
Cash Ratio | 5.94 | |||||
Days Inventory | 407.23 | |||||
Days Sales Outstanding | 37.58 | |||||
Days Payable | 3080.08 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -34.4 | |||||
Shareholder Yield % | 0.15 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 76.51 | |||||
Operating Margin % | -3700.89 | |||||
Net Margin % | -3566.63 | |||||
EBITDA Margin % | -3514 | |||||
FCF Margin % | -3565.86 | |||||
OCF Margin % | -3513.32 | |||||
ROE % | -106 | |||||
ROA % | -86.63 | |||||
ROIC % | -582.46 | |||||
3-Year ROIIC % | -724.88 | |||||
ROC (Joel Greenblatt) % | -915.81 | |||||
ROCE % | -97.26 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 131.9 | |||||
PB Ratio | 5.01 | |||||
Price-to-Tangible-Book | 5.01 | |||||
EV-to-EBIT | -3.55 | |||||
EV-to-EBITDA | -3.58 | |||||
EV-to-Revenue | 125.92 | |||||
EV-to-Forward-Revenue | 558.79 | |||||
EV-to-FCF | -3.53 | |||||
Price-to-GF-Value | 18.47 | |||||
Price-to-Median-PS-Value | 14.58 | |||||
| Price-to-Net-Current-Asset-Value | 6.02 | |||||
| Price-to-Net-Cash | 7.03 | |||||
Earnings Yield (Greenblatt) % | -28.17 | |||||
FCF Yield % | -23.38 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:EYPT
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
EyePoint Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 7.615 | ||
| EPS (TTM) ($) | -3.5 | ||
| Beta | 2.5516 | ||
| 3-Year Sharpe Ratio | 0.49 | ||
| 3-Year Sortino Ratio | 1.72 | ||
| Volatility % | 63.12 | ||
| 14-Day RSI | 51.03 | ||
| 14-Day ATR ($) | 0.957101 | ||
| 20-Day SMA ($) | 13.94825 | ||
| 12-1 Month Momentum % | 22.76 | ||
| 52-Week Range ($) | 9.4 - 19.11 | ||
| Shares Outstanding (Mil) | 83.84 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
EyePoint Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
EyePoint Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-05 08:30 | In 113 days | ||
| Third quarter earnings results for 2026 | 2026-11-05 | In 112 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-06 08:30 | In 22 days | ||
| Second quarter earnings results for 2026 | 2026-08-06 | In 21 days | ||
| General meeting for 2026 | 2026-06-18 09:00 | 13.15 (+2.02%) | ||
| Goldman Sachs 47th Annual Global Healthcare Conference | 2026-06-09 11:20 | 11.45 (-3.78%) | ||
| Jefferies Global Healthcare Conference | 2026-06-03 16:55 | 12.53 (-4.13%) | ||
| Guidance call for 2026 | 2026-05-26 09:00 | 12.93 (+0.47%) | ||
| First quarter earnings conference call for 2026 | 2026-05-06 08:30 | 13.75 (-0.79%) | ||
| First quarter earnings results for 2026 | 2026-05-06 | 13.75 (-0.79%) |
Show
Entries
EyePoint Inc Frequently Asked Questions
What is EyePoint Inc(EYPT)'s stock price today?
The current price of EYPT is $13.85. The 52 week high of EYPT is $19.11 and 52 week low is $9.40.
When is next earnings date of EyePoint Inc(EYPT)?
The next earnings date of EyePoint Inc(EYPT) is 2026-08-06 Est..
Does EyePoint Inc(EYPT) pay dividends? If so, how much?
EyePoint Inc(EYPT) does not pay dividend.
Guru Commentaries on NAS:EYPT
No articles.
Press Release
Articles on EyePoint Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers